Incyte upgraded to Buy on strong pipeline progress and promising Phase 3 data for Monjuvi.

Incyte to acquire Vega Therapeutics for $2B, expanding into bleeding disorder treatments.

Incyte Corporation will acquire Vega Therapeutics for up to $2 billion to expand its portfolio into bleeding disorder treatments, including a late-stage drug candidate for von Willebrand disease. Analyst firm Oppenheimer maintained a "Perform" rating...